BI
BIOYF.US Biosyent Inc.
- Market cap
- USD 140M
- P/E
- 20.0x
- P/B
- 4.35x
- ROE
- 22.7%
- Dividend yield
- 1.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BIOYF.US undervalued?
Graham numberBIOYF.US trades 96.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biosyent Inc. fundamental analysis
No fundamental analysis for Biosyent Inc. yet.
Biosyent Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibe…
Full company profileBiosyent Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biosyent Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.9M | 20.8M | 21.5M | 21.4M | 22.3M | 28.6M | 27.9M | 31.6M | 35.0M | 43.0M | 67.7M |
| Gross Profit | 14.1M | 16.0M | 16.6M | 16.6M | 17.4M | 22.6M | 22.9M | 25.6M | 27.9M | 32.1M | 45.3M |
| Operating Income | 5.75M | 6.85M | 6.37M | 5.39M | 5.03M | 8.18M | 6.98M | 7.47M | 8.75M | 11.3M | 14.2M |
| EBITDA | 5.86M | 6.57M | 6.55M | 6.19M | 5.54M | 8.64M | 7.43M | 7.93M | 10.4M | 12.2M | 17.3M |
| Net Income | 4.31M | 5.21M | 5.71M | 4.37M | 3.80M | 6.28M | 5.46M | 6.46M | 7.27M | 9.00M | 10.4M |
| EPS | 0.30 | 0.36 | 0.39 | 0.31 | 0.29 | 0.49 | 0.44 | 0.53 | 0.64 | 0.78 | 0.89 |
| Balance Sheet | |||||||||||
| Total Assets | 19.2M | 25.1M | 31.2M | 31.0M | 33.6M | 37.2M | 40.5M | 41.5M | 41.4M | 49.4M | 60.5M |
| Total Liabilities | 2.52M | 2.89M | 3.58M | 5.17M | 6.78M | 5.61M | 7.12M | 6.77M | 6.36M | 7.97M | 14.6M |
| Shareholders' Equity | 16.7M | 22.2M | 27.6M | 25.8M | 26.8M | 31.6M | 33.4M | 34.8M | 35.0M | 41.4M | 45.9M |
| Cash & Short-term Investments | 13.7M | 19.3M | 24.4M | 22.0M | 25.6M | 28.2M | 28.7M | 26.2M | 15.9M | 28.6M | 8.95M |
| Total Debt | - | - | - | 1.85M | 1.71M | 1.56M | 1.40M | 1.22M | 1.04M | 840K | 3.14M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.40M | 6.55M | 6.29M | 4.77M | 6.89M | 4.67M | 4.95M | 5.05M | 8.66M | 9.61M | 11.0M |
| Capital Expenditure | 405K | 640K | 504K | 734K | 174K | 93.2K | 519K | 174K | 4.67M | 54.0K | 89.4K |
| Free Cash Flow | 3.99M | 5.91M | 5.78M | 4.04M | 6.72M | 4.58M | 4.43M | 4.88M | 3.99M | 9.56M | 10.9M |
| Ratios | |||||||||||
| ROE | 25.8% | 23.4% | 20.7% | 16.9% | 14.2% | 19.9% | 16.4% | 18.6% | 20.8% | 21.7% | 22.7% |
| ROA | 22.4% | 20.7% | 18.3% | 14.1% | 11.3% | 16.9% | 13.5% | 15.6% | 17.6% | 18.2% | 17.2% |
| Net Profit Margin | 24.0% | 25.1% | 26.5% | 20.4% | 17.0% | 21.9% | 19.5% | 20.4% | 20.8% | 20.9% | 15.4% |
| Debt to Equity | - | - | - | 0.07x | 0.06x | 0.05x | 0.04x | 0.04x | 0.03x | 0.02x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biosyent Inc. dividends
- Dividend yield
- 1.27%
- Forward dividend
- 0.16 USD
- Payout ratio
- 25.0%
- Ex-dividend date
- Aug 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CAD 2.25M | 0.20 | 25.0% |
| 2024 | CAD 2.08M | 0.18 | 28.6% |
| 2023 | CAD 1.91M | 0.16 | 29.6% |
| 2022 | CAD 484K | 0.04 | 8.9% |
| 2021 | USD 10.3K | 0.00 | 0.2% |
| 2020 | USD 7.42K | 0.00 | 0.2% |
| 2019 | USD 4.72K | 0.00 | 0.1% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Biosyent Inc.
- Insiders 39.57%
- Institutions 4.15%
- Public & others 56.29%
- Shares outstanding 11.2M
- Free float 9.14M
Biosyent Inc. company profile
- Company name
- Biosyent Inc.
- Ticker
- BIOYF.US
- ISIN
- CA0906901081
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1
- Phone
- 905-206-0013
- Website
- biosyent.com
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
Biosyent Inc. management
5- Mr. René C. GoehrumChairman, CEO & President · born 1959
- Mr. Robert J. MarchVP of Finance & CFO
- Mr. Joost van der MarkVice President of Corporate Development
- Ms. Marnie MccormickVP & GM
- Ms. Neelu AtwalDirector of Human Resources